danafarberbostonchildrens.org
Jun 23, 2025, 11:22
Riten Kumar Shared New ISTH Data: 3-Month Apixaban Course Shows Better Safety Profile Than Rivaroxaban in Acute VTE
Riten Kumar, Associate Professor of Pediatrics at Harvard, posted on X:
“Late breaking abstract at isth – 3 months of apixaban is safer than rivaroxaban for management of acute VTE!!!”
Be updated with Hemostasis Today.
-
Apr 14, 2026, 15:36Alisha Tuck: Navigating the First Trimester with Ultrasound and Anticoagulation Management
-
Apr 14, 2026, 15:26Tijjani Balas: The End of ‘Type O Negative’ Shortages? – A New Era in Blood Transfusion
-
Apr 14, 2026, 15:07Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
-
Apr 14, 2026, 15:05Matteo Foschi: ASPERA-R Study Reveals Competing Causes Of Breakthrough Stroke On Anticoagulation
-
Apr 14, 2026, 14:48Samwel Mikaye: From Virchow’s Triad to Prevention of PE in Patients with DVT
-
Apr 14, 2026, 14:43Chokri Ben Lamine: Diamond – Blackfan Anemia and Congenital Dyserythropoietic Anemia Pearls
-
Apr 14, 2026, 14:14From the Clinical Transfusion Working Party – 2025 International Platelet Transfusion Guidelines – ISBT
-
Apr 14, 2026, 13:48Antoine Francis: This Is What a Donation Actually Becomes
-
Apr 14, 2026, 13:09Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology